Press release
Antibody-mediated Rejection Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi
DelveInsight's "Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Antibody-mediated Rejection, historical and forecasted epidemiology as well as the Antibody-mediated Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Antibody-mediated Rejection market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Antibody-mediated Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody-mediated Rejection Market Insights https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Antibody-mediated Rejection Overview
End-stage organ diseases are responsible for millions of deaths worldwide each year. Organ transplantation has become the treatment of choice, but despite the ever-increasing organ transplantations performed each year, only 1million persons worldwide have functioning solid-organ transplants because of the lack of improvement in long-term allograft survival over the past few decades and the limited organ supply.
Some of the key facts of the Antibody-mediated Rejection Market Report:
• The Antibody-mediated Rejection market size was valued at USD 85.47 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total incident population of Antibody-mediated rejection (AMR) in the 7MM was estimated to be 5,027 cases in 2019
• The United States showed the highest incident population of Antibody-mediated Rejection in kidney transplants. In 2019, the total incidence of kidney transplants in the United States was found to be 1,887 cases
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), BIVV020, and others
• The Antibody-mediated Rejection epidemiology based on gender analyzed that both males and females are affected equally by Antibody-mediated Rejection (AMR)
Get a Free sample for the Antibody-mediated Rejection Market Report
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Key benefits of the Antibody-mediated Rejection Market report:
1. Antibody-mediated Rejection market report covers a descriptive overview and comprehensive insight of the Antibody-mediated Rejection Epidemiology and Antibody-mediated Rejection market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Antibody-mediated Rejection market report provides insights on the current and emerging therapies.
3. Antibody-mediated Rejection market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Antibody-mediated Rejection market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Antibody-mediated Rejection market.
Download the report to understand which factors are driving Antibody-mediated Rejection epidemiology trends @ Antibody-mediated Rejection Epidemiological Insights
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Antibody-mediated Rejection Market
The dynamics of the Antibody-mediated Rejection market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
"Even though new Antibody-mediated Rejection therapies are promising, randomized controlled trials are needed to find surrogate markers and improve the efficacy of therapy"
Antibody-mediated Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Antibody-mediated Rejection Epidemiology Segmentation:
The Antibody-mediated Rejection market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Antibody-mediated Rejection
• Prevalent Cases of Antibody-mediated Rejection by severity
• Gender-specific Prevalence of Antibody-mediated Rejection
• Diagnosed Cases of Episodic and Chronic Antibody-mediated Rejection
Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched during the study period. The analysis covers Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Antibody-mediated Rejection market share @ Antibody-mediated Rejection market forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Antibody-mediated Rejection Therapies and Key Companies
• Clazakizumab: CSL Behring
• Imlifidase: Hansa Biopharma
• VIB4920 (HZN-4920): Horizon Therapeutics
• BIVV020: Sanofi
Antibody-mediated Rejection Market Drivers
• Emerging Antibody-mediated Rejection Therapy
• Development of Personalized Therapy
• Targeting of Novel Pathways
• Increased Rate of Organ Donation
• Development of Gene therapy
Scope of the Antibody-mediated Rejection Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), BIVV020, and others
• Antibody-mediated Rejection Therapeutic Assessment: Antibody-mediated Rejection current marketed and Antibody-mediated Rejection emerging therapies
• Antibody-mediated Rejection Market Dynamics: Antibody-mediated Rejection market drivers and Antibody-mediated Rejection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Antibody-mediated Rejection Unmet Needs, KOL's views, Analyst's views, Antibody-mediated Rejection Market Access and Reimbursement
Antibody-mediated Rejection Market Barriers
• Challenges in Designing Clinical Trials
• Need for Evidence-based Treatment Guidelines
• High Clinical Burden
Table of Contents
1. Antibody-mediated Rejection Market Report Introduction
2. Executive Summary for Antibody-mediated Rejection
3. SWOT analysis of Antibody-mediated Rejection
4. Antibody-mediated Rejection Patient Share (%) Overview at a Glance
5. Antibody-mediated Rejection Market Overview at a Glance
6. Antibody-mediated Rejection Disease Background and Overview
7. Antibody-mediated Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Antibody-mediated Rejection
9. Antibody-mediated Rejection Current Treatment and Medical Practices
10. Antibody-mediated Rejection Unmet Needs
11. Antibody-mediated Rejection Emerging Therapies
12. Antibody-mediated Rejection Market Outlook
13. Country-Wise Antibody-mediated Rejection Market Analysis (2019-2032)
14. Antibody-mediated Rejection Market Access and Reimbursement of Therapies
15. Antibody-mediated Rejection Market Drivers
16. Antibody-mediated Rejection Market Barriers
17. Antibody-mediated Rejection Appendix
18. Antibody-mediated Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Antibody-mediated Rejection treatment, visit @ Antibody-mediated Rejection Medications
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Antibody-mediated Rejection Pipeline https://www.delveinsight.com/report-store/antibody-mediated-graft-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Antibody-mediated Rejection Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Antibody-mediated Rejection market. A detailed picture of the Antibody-mediated Rejection pipeline landscape is provided, which includes the disease overview and Antibody-mediated Rejection treatment guidelines.
Antibody-mediated Rejection Epidemiology https://www.delveinsight.com/report-store/antibody-mediated-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Antibody-mediated Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Antibody-mediated Rejection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Trending Reports by DelveInsight
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody-mediated Rejection Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi here
News-ID: 2769668 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Rejection
Antibody-mediated Rejection Market Dynamics, Innovations and Growth
Organ transplantation has been one of the most remarkable achievements of modern medicine, offering patients with end-stage organ failure a renewed chance at life. However, antibody-mediated rejection (AMR) remains a major complication following kidney, heart, lung, and liver transplants, significantly affecting long-term graft survival. AMR occurs when donor-specific antibodies (DSAs) attack the transplanted organ, leading to immune injury and often graft loss.
Download Full PDF Sample Copy of Market Report @…
Global Nitrogen Rejection Units Market Analysis (2024-2029)
LPI (LP Information)' newest research report, the "Nitrogen Rejection Units Industry Forecast" looks at past sales and reviews total world Nitrogen Rejection Units sales in 2024, providing a comprehensive analysis by region and market sector of projected Nitrogen Rejection Units sales for 2024 through 2029. With Nitrogen Rejection Units sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world…
Transplant Rejection Treatment Market-Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Transplant Rejection Treatment Market is projected to grow from USD 5.6 billion in 2021 to USD 6.9 billion by 2026 at a CAGR value of 4.2% from 2021 to 2026.
Increasing number of research and developmental activities related to transplant rejection procedure, increasing demand for transplant surgeries, rising chronic disease prevalence and high disposable income are…
Bone Marrow Transplant Rejection - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Bone Marrow Transplant Rejection - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.
Bone marrow transplant rejection is a complication that can occur after a stem…
Jobbatical brings candidate rejection messaging to Jobbatical.com
Tallinn, Estonia – June 8, 2017 – Jobbatical product innovation continues with the ability to send rejection messaging to candidates directly from our platform.
Jobbatical continues to make it easier for hiring managers to source and evaluate applicants on our platform. Now we’ve implemented an easy to use rejection function with the option to use a template letter or personalized response to reject the candidate. As a hiring manager, it’s…
Liver Transplant Rejection - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Liver Transplant Rejection - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.
Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability…
